FDA DEVICE FACTS
UCP COMPACT DRUG TESTS
Ucp Biosciences, Inc.
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
UCP Compact Drug Tests Cards and UCP Compact Drug Tests Cups are rapid, qualitative, competitive binding immunoassays for qualitatively the detection of the following drugs and their metabolites in human urine at the following cut-off concentrations:
Test Calibrator Cut-off Marijuana: Delta-9-THC-COOH 50 ng/mL Cocaine: Benzoylecgonine 300 ng/mL Amphetamine: D-Amphetamine 1000 ng/mL Methamphetamine: D-Methamphetamine 1000 ng/mL Opiates: Morphine 2000 ng/mL Morphine: Morphine 300 ng/mL Phencyclidine: Phencyclidine 25 ng/mL Barbiturates: Secobarbital 300 ng/mL Benzodiazepines: Oxazepam 300 ng/mL Buprenorphine Buprenorphine 10 ng/mL Methadone: Methadone 300 ng/mL EDDP: EDDP 300 ng/mL Oxycodone: Oxycodone 100 ng/mL MDMA: MDMA 500 ng/mL Propoxyphene Propoxyphene 300 ng/mL Tricyclic Antidepressants: Nortriptyline 1000 ng/mL
The tests are intended for over-the-counter (OTC) consumer use as the first step in a two step process to provide the consumers with information concerning the presence or absence of the above stated drugs or their metabolites in a urine sample. Information regarding confirmatory test in the second step of the two-step process, is provided in the package labeling.
The test configuration comes with single drug screening test or any combinations of multiple drug screening tests. The tests will yield preliminary positive results when the prescription drugs Barbiturates, Benzodiazepines, Buprenorphine, Oxycodone, Propoxyphene, Tricyclic Antidepressants are ingested, even at or above therapeutic doses. There are no uniformly recognized drug levels for Barbiturate, Benzodiazepines, Buprenorphine, Oxycodone, Propoxyphene, Tricyclic Antidepressant in urine. The multi-drug of abuse urine test device shows the drug was or was not present at the cutoff level. The tests provide only preliminary test results, which must be confirmed by other methods such as gas chromatography/mass spectrometry (GC/MS). Clinical considerations and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated. The tests are not intended to be used in monitoring the drug levels.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。